Results 71 to 80 of about 449,109 (258)

IL33 in rheumatoid arthritis: potential contribution to pathogenesis

Revista Brasileira de Reumatologia
A better understanding of the inflammatory mechanisms of rheumatoid arthritis and the development of biological therapy revolutionized its treatment, enabling an interference in the synovitis – structural damage – functional disability cycle. Interleukin
Rafaela Bicalho Viana Macedo, Adriana Maria Kakehasi, Marcus Vinicius Melo de Andrade   +2 more
doaj   +1 more source

Higher interleukin-33 levels in aggressive periodontitis cases

Journal of Indian Society of Periodontology, 2019
Context: Interleukin-33 (IL-33) is a novel alarmin that warns immune cells of tissue destruction in injury or infection. Aims: This study is aimed at analyzing and correlating the concentration of IL-33 in the gingival crevicular fluid (GCF) and plasma ...
Sujatha Pai Ballambettu, A R Pradeep, Meera Purushottam, Somdatta Sen   +3 more
doaj   +1 more source

Real‐World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity‐Matched Study From the EUSTAR Cohort

Arthritis Care &Research, EarlyView.
Objective JAK inhibitors (JAKi) have shown promising effects in early‐phase studies of systemic sclerosis (SSc). We aimed to assess the safety and explore the effectiveness of JAKi compared to conventional immunosuppressants in SSc. Methods A longitudinal retrospective study of the European Scleroderma Trials and Research Group (EUSTAR) cohort was ...
Stefano Di Donato, Marie‐Elise Truchetet, Marco Minerba, Oliver Distler, Juan José Alegre Sancho, Yolanda Braun‐Moscovici, Christina Bergmann, Petros Sfikakis, Jeska K. de Vries‐Bouwstra, Murray Baron, Silvia Bellando‐Randone, Lorenzo Dagna, Christopher P. Denton, Madelon C. Vonk, Vanessa Smith, Ivan Castellvi, Gabriela Riemekasten, Andra Balanescu, Masataka Kuwana, Maria De Santis, Kamal Solanki, Anastas Batalov, Vahan Mukuchyan, Marco Matucci‐Cerinic, Yannick Allanore, Francesco Del Galdo, Michael Hughes, EUSTAR Collaborators   +27 more
wiley   +1 more source

Interleukin-33: Its Emerging Role in Allergic Diseases

Molecules, 2018
Allergic diseases, which include asthma, allergic rhinitis (AR), chronic rhinosinusitis (CRS), atopic dermatitis (AD), food allergy (FA), allergic keratoconjunctivitis, seriously affect the quality of life of people all over the world.
Wen Ding, Gui-Lin Zou, Wei Zhang, Xing-Ning Lai, Hou-Wen Chen, Li-Xia Xiong   +5 more
doaj   +1 more source

Interleukin-33 (IL-33) as a Diagnostic and Prognostic Factor in Traumatic Brain Injury

Emergency Medicine International, 2020
Interleukin-33 (IL-33) is a cytokine involved in interleukin-1 family. Role of IL-33 in immune system activation is well described in the literature. IL-33 has been identified as an endogenous alarm signal (alarmin) to alert various types of immune cells
Ali Kemal Erenler, Ahmet Baydin
doaj   +1 more source

From Adult to Adolescent: Alignment in Clinical Trials and Outcomes in Axial Spondyloarthritis

Arthritis Care &Research, Accepted Article.
Spondyloarthritis (SpA) is a group of chronic inflammatory diseases encompassing axial and peripheral forms, with up to 20% of patients developing symptoms before age 16. Despite this substantial pediatric burden, treatment options for juvenile‐onset SpA (JSpA), particularly those with axial disease (axJSpA), remain limited.
Pamela F. Weiss, Judith A. Smith, Robert A. Colbert, Erin Treemarcki, Michael H. Weisman, Walter P. Maksymowych, Hermine I. Brunner, for the CARRA, SPARTAN, and PRCSG Advisory Council   +9 more
wiley   +1 more source

Serum levels of Interleukin-33 and its soluble receptor ST2 in asthmatic patients

Egyptian Journal of Chest Disease and Tuberculosis, 2014
Interleukin-33 is a member of IL-1 family of cytokines and binds to two receptors: ST2 (IL-1-R1) and IL-1 receptor accessory protein (IL-1RAP). There are two isoforms of ST2 proteins: ST2L, a transmembrane form, and a soluble ST2 (sST2), a secreted form,
Ensaf A. Azazi, Ashraf E. Elshora, Enas A. Tantawy, Marwa A. Elsayd   +3 more
doaj   +1 more source

Short‐term response to biologic therapy in psoriatic arthritis (PsA) is not influenced by disease duration at initiation of therapy

Arthritis Care &Research, Accepted Article.
Objectives We aimed to determine whether the short‐term response to biologics in biologic‐naïve psoriatic arthritis (PsA) is better in patients initiating biologic treatment early in the disease course. Methods PsA patients who started biologic therapy from the year 2000 to 2025 were included for analysis. Patients considered in the early treatment (ET)
Sung Min Cho, Shangyi Gao, Daniel Pereira, Richard J. Cook, Dafna D. Gladman   +4 more
wiley   +1 more source

Strain‐Programmable Luminescent Adhesive Patch With Tartrazine‐Mediated Optical Skin Clearing for Photochemical Tissue Bonding

Advanced Functional Materials, EarlyView.
We propose a suture‐complementary approach that integrates optical skin clearing with a strain‐programmable luminescent adhesive patch. Hyaluronic acid promotes transdermal delivery of tartrazine to improve optical clearing and stabilizes its interaction with a photosensitizer. Optical clearing increases the penetration depth of visible light into skin,
Seong‐Jong Kim, Kyungjoo Jo, Kwanghyeon Park, Jun Hee Kim, Jong Hyeong Cho, Inhoo Choi, Sei Kwang Hahn   +6 more
wiley   +1 more source

IL-25, IL-33 and TSLP receptor are not critical for development of experimental murine malaria

Biochemistry and Biophysics Reports, 2016
IL-25, IL-33 and TSLP, which are produced predominantly by epithelial cells, can induce production of Th2-type cytokines such as IL-4, IL-5 and/or IL-13 by various types of cells, suggesting their involvement in induction of Th2-type cytokine-associated ...
Akiko Shibui, Ayako Takamori, Mohammed E.M. Tolba, Aya Nambu, Eri Shimura, Sachiko Yamaguchi, Chizu Sanjoba, Hajime Suto, Katsuko Sudo, Ko Okumura, Sumio Sugano, Hideaki Morita, Hirohisa Saito, Kenji Matsumoto, Susumu Nakae   +14 more
doaj   +1 more source